Osteoporosis treatment typically starts with calcium and vitamin D supplements, but most people diagnosed with the condition will also need prescription medication to reduce fracture risk. The right combination depends on how severe your bone loss is, whether you’ve already had a fracture, and your overall health profile. Here’s what’s available and how each option works.
Calcium and Vitamin D: The Foundation
Every osteoporosis treatment plan starts with ensuring your body has the raw materials it needs to maintain bone. Calcium provides the structural mineral, and vitamin D helps your intestines absorb it. Without adequate levels of both, prescription medications won’t work as well.
Most adults with osteoporosis need 1,000 to 1,200 mg of calcium daily from food and supplements combined. If you’re supplementing, you’ll encounter two main forms: calcium carbonate and calcium citrate. Calcium citrate is absorbed more easily, can be taken on an empty stomach, and works better for people who take acid-reducing heartburn medications. Calcium carbonate requires stomach acid to absorb properly, so it should be taken with food. Either form works, but splitting your dose into 500 mg portions improves absorption regardless of which you choose.
For vitamin D, blood levels at or above 20 ng/mL are generally considered adequate for bone health, while levels below 12 ng/mL are associated with deficiency. Levels above 50 ng/mL may cause harm. Most people with osteoporosis supplement with 800 to 2,000 IU of vitamin D3 daily, though your doctor may recommend more if your blood levels are low.
Bisphosphonates: The Most Common Starting Point
Bisphosphonates are the most widely prescribed osteoporosis drugs. They work by slowing the cells that break down bone, allowing your skeleton to hold onto more of the bone it builds. The group includes alendronate, risedronate, ibandronate, and zoledronic acid, available in oral and intravenous forms with weekly, monthly, or annual dosing schedules depending on the specific drug.
The fracture protection is significant. Bisphosphonates reduce the risk of spinal fractures by 60 to 70% within the first year of treatment. For hip fractures, the reduction is 40 to 50%, and for other non-spinal fractures, 20 to 30%. One exception: ibandronate has not been shown to reduce hip or non-spinal fracture risk, so it’s typically reserved for people whose primary concern is spinal fractures.
Oral bisphosphonates need to be taken on an empty stomach with a full glass of water, and you must stay upright for at least 30 minutes afterward to avoid irritation of the esophagus. This routine bothers some people enough that they prefer the intravenous option, zoledronic acid, which is given as a once-yearly infusion.
Bisphosphonate Drug Holidays
Unlike most medications, bisphosphonates accumulate in bone and continue working for months or years after you stop taking them. This creates the opportunity for a “drug holiday,” where you pause treatment while still retaining some protective benefit. Professional guidelines recommend considering a break after 3 to 5 years in patients at lower fracture risk. The rationale is partly practical: long-term bisphosphonate use is linked to two rare but serious complications, atypical fractures of the thigh bone and bone deterioration in the jaw. Pausing treatment may reduce these risks. Your doctor will reassess your bone density and fracture risk to decide whether and when to restart.
Bone-Building Medications
Bisphosphonates slow bone loss, but a different class of drugs actively builds new bone. These are called anabolic agents, and they work by stimulating the cells responsible for bone formation. Two are currently available: teriparatide and abaloparatide. Both mimic the action of parathyroid hormone, a natural signal that tells your body to form new bone.
Abaloparatide tends to increase bone density faster and to a greater degree than teriparatide, based on differences in how the two drugs bind to the same receptor. Both are given as daily self-injections under the skin. Treatment with teriparatide was originally limited to two years over a patient’s lifetime due to concerns about bone cancer seen in animal studies, but the FDA removed that boxed warning in 2020. The updated guidance allows use beyond two years if a patient remains at high fracture risk, though most treatment courses still run about 18 to 24 months.
These drugs are typically reserved for people with very low bone density, those who have already fractured a bone, or patients whose bone loss has continued despite bisphosphonate treatment. One critical detail: after you stop a bone-building drug, you need to transition to a bisphosphonate or another maintenance medication. Without follow-up treatment, the new bone you gained can be lost relatively quickly.
Romosozumab: Building and Protecting at Once
Romosozumab is the newest osteoporosis drug and the only one that both stimulates bone formation and suppresses bone breakdown at the same time. It blocks a protein called sclerostin that normally puts the brakes on bone building. The result is a rapid increase in bone density over a 12-month treatment course, delivered as two injections once a month.
Like other bone-building drugs, romosozumab requires a transition to maintenance therapy afterward. Stopping without follow-up treatment can trigger a rebound in bone breakdown, similar to what happens when another drug, denosumab, is discontinued. Romosozumab carries a cardiovascular caution: it’s not recommended for people who have had a heart attack or stroke within the past year, and doctors weigh cardiovascular risk carefully before prescribing it.
Denosumab: A Different Approach to Slowing Bone Loss
Denosumab works differently from bisphosphonates, though the end result is similar: it slows bone breakdown. It’s a targeted antibody that neutralizes a signal (called RANKL) that bone-destroying cells need to form and survive. Without that signal, fewer of these cells mature, and bone loss slows dramatically.
The dosing is straightforward: one injection under the skin every six months, given in a doctor’s office. That schedule needs to be maintained closely, within a two-week window in either direction. Missing or delaying doses can cause a rapid rebound in bone loss that may actually increase fracture risk above where it was before treatment started. For this reason, denosumab is considered a long-term commitment. If you and your doctor decide to stop it, you’ll need to transition to a bisphosphonate to prevent rebound bone loss.
Raloxifene for Postmenopausal Women
Raloxifene belongs to a class of drugs that mimic estrogen’s protective effects on bone without being estrogen itself. It’s approved only for postmenopausal women and serves a dual purpose: it helps prevent and treat osteoporosis while also lowering the chance of invasive breast cancer. This makes it a particularly useful option for postmenopausal women who are at elevated breast cancer risk.
The trade-off is that raloxifene’s fracture protection is more modest than what bisphosphonates or bone-building drugs offer, and it primarily reduces spinal fractures rather than hip fractures. It also increases the risk of blood clots, so it’s not appropriate for women with a history of deep vein thrombosis or pulmonary embolism.
How Treatment Is Sequenced
The order in which you take osteoporosis drugs matters. For people at moderate risk, treatment often starts with a bisphosphonate and may continue for 3 to 5 years before a reassessment. For those at very high risk, such as someone with very low bone density or a recent fracture, current practice increasingly favors starting with a bone-building agent like teriparatide or romosozumab first, then transitioning to a bisphosphonate or denosumab for long-term maintenance. This “build first, protect second” approach produces greater gains in bone density than starting with a bisphosphonate alone.
The sequencing also matters in reverse. Starting with a bisphosphonate and then switching to teriparatide blunts the bone-building drug’s effectiveness, because bisphosphonates suppress the very bone remodeling that anabolic agents rely on. If a bone-building agent is likely to be part of your treatment plan at some point, starting with it yields better long-term results.